- World rank, 2022–2025
- #20,186 of 28,054 · #37,549 all time
- Rank in China
- #2,869 of 3,058
- Research works
- 136 ▲ 512% vs 2013–17
- Citations
- 1.3k 9.3 per fractional work
- Top-10% rate
- 12.9% record average 16.5%
- Open access
- 65% world 28%
What does Dian Diagnostics (China) specialise in?
Where its research is concentrated relative to its size: Biochemistry, Genetics and Molecular Biology takes 4.6× the share of its output that it takes of world research.
- Biochemistry, Genetics and Molecular BiologyField · 20.2 works4.6×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.6×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 4.6×
- Immunology and Microbiology 3.3×
- Medicine 3.1×
- Veterinary 2.0×
- Neuroscience 1.1×
- Dentistry 1.0×
- Nursing 1.0×
- Pharmacology, Toxicology and Pharmaceutics 1.0×
- Energy 0.4×
- Agricultural and Biological Sciences 0.3×
- Engineering 0.2×
- Materials Science 0.2×
- Health Professions 0.1×
- Decision Sciences 0.1×
- Chemistry 0.1×
- Environmental Science 0.1×
- Computer Science 0.1×
- Mathematics 0.1×
- Physics and Astronomy 0.1×
- Earth and Planetary Sciences 0.1×
- Psychology 0.0×
- Social Sciences 0.0×
Which keywords describe research at Dian Diagnostics (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer, Targeted Therapy, Tumor Microenvironment, Epidemiology, Clinical Trials, Chemotherapy, Cell Death and Prognostic Factors.
- Genomic Profiles
- GPX4
- BRAF Mutation
- Lipid Peroxidation
- Neoadjuvant Therapy
- Synthetic Lethality
- Genetic Mutations
- Clinical Practice Guidelines
- Diagnosis
- Treatment
- PD-1 and PD-L1
- Genomic Instability
- ALK Inhibitors
- Biomarkers
- Oxidative Stress
- Gene Expression
- Inflammation
- Chemotherapy
- Tumor Microenvironment
- Cancer
- Epidemiology
- Targeted Therapy
- Clinical Trials
- Cell Death
- Prognostic Factors
- Immunotherapy
- Treatment Guidelines
- Homologous Recombination
- EGFR Mutations
- Immune Checkpoint Blockade
- Precision Medicine
- Cancer Therapy
- Metastasis
- Breast Cancer
- Radiotherapy
- BRCA Mutation
- PARP Inhibitors
- Survival Analysis
- Ferroptosis
- Cell-Free DNA
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology9▲ 2.8×43 topics
- Cancer8▲ 7.2×24 topics
- Targeted Therapy7▲ 37×4 topics
- Tumor Microenvironment6▲ 17×8 topics
- Clinical Trials5▲ 9.7×4 topics
- Chemotherapy5▲ 9.1×13 topics
- Cell Death4▲ 22×5 topics
- Inflammation4▲ 2.5×34 topics
- Prognostic Factors4▲ 11×7 topics
- Gene Expression4▲ 7.9×10 topics
- Immunotherapy4▲ 6.7×13 topics
- Oxidative Stress4▲ 2.8×18 topics
- Treatment Guidelines4▲ 20×3 topics
- Biomarkers4▲ 6.2×10 topics
- Homologous Recombination4▲ 94×2 topics
- ALK Inhibitors3▲ 64×1 topic
- EGFR Mutations3▲ 64×1 topic
- Genomic Instability3▲ 34×2 topics
- Immune Checkpoint Blockade3▲ 34×1 topic
- PD-1 and PD-L13▲ 34×1 topic
- Precision Medicine3▲ 8.0×6 topics
- Treatment3▲ 3.1×15 topics
- Cancer Therapy3▲ 6.3×6 topics
- Diagnosis3▲ 3.8×15 topics
- Metastasis3▲ 10×5 topics
- Clinical Practice Guidelines2▲ 5.2×6 topics
- Breast Cancer2▲ 11×5 topics
- Genetic Mutations2▲ 6.1×12 topics
- Radiotherapy2▲ 6.8×4 topics
- Synthetic Lethality2▲ 81×2 topics
- BRCA Mutation2▲ 107×1 topic
- Neoadjuvant Therapy2▲ 10×4 topics
- PARP Inhibitors2▲ 107×1 topic
- Lipid Peroxidation2▲ 22×2 topics
- Survival Analysis2▲ 8.5×4 topics
- BRAF Mutation2▲ 30×2 topics
- Ferroptosis2▲ 29×1 topic
- GPX42▲ 29×1 topic
- Cell-Free DNA2▲ 21×2 topics
- Genomic Profiles2▲ 48×1 topic
Which research topics does Dian Diagnostics (China) publish most on?
By volume in 2022–2025: Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy and Ferroptosis and cancer prognosis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 3 PARP inhibition in cancer therapy Oncology 2 works
- 4 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 2 works
- 5 Lung Cancer Research Studies Oncology 2 works
- 6 Cancer Genomics and Diagnostics Cancer Research 2 works
- 7 DNA Repair Mechanisms Molecular Biology 2 works
- 8 Acute Myeloid Leukemia Research Hematology 1 works
- 9 Thyroid Cancer Diagnosis and Treatment Endocrinology, Diabetes and Metabolism 1 works
- 10 Mycobacterium research and diagnosis Epidemiology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Dian Diagnostics (China)'s research output changed?
Output in 2018–2022 was 512% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Hangzhou
- Zhejiang University
- Zhejiang University of Technology
- Hangzhou Dianzi University
- Zhejiang Sci-Tech University
- China Jiliang University
- Hangzhou Normal University
- Zhejiang Chinese Medical University
- Zhejiang Gongshang University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.